Stanley North

The appellants appealed the dismissal of their motion for certification of a proposed class proceeding against the manufacturers of the anti-coagulant drug Pradaxa.

The appellants alleged the respondents breached a duty to warn that there was no antidote for the drug.

The motions judge found that the duty to warn was not a common issue, concluding there was no basis in fact that the failure to warn was a source of harm common across the class.

On appeal, the Divisional Court held that the motions judge did not err in principle or impermissibly weigh competing expert evidence, but correctly applied the 'some basis in fact' test using undisputed evidence.

The appeal was dismissed.

The plaintiffs brought a motion for certification of a class action against the manufacturers of Pradaxa, an anticoagulant drug.

The plaintiffs alleged that the defendants breached their duty to warn consumers and healthcare professionals about the lack of an antidote for the drug, which could lead to excessive bleeding.

The court dismissed the certification motion, finding that the plaintiffs failed to establish that the proposed common issues actually existed or could be answered in common across the class.

The court noted that the decision to prescribe an anticoagulant and the need for a reversal agent are highly patient-specific, and there was no basis in fact to conclude that the absence of an antidote posed a common and material risk across the class.